Last updated: April 25, 2026
What is CN100577234 and where does it sit in the China patent landscape?
CN100577234 (China published patent application; publication year 2010) is part of a standard China small-molecule or biologics-style patent stack in which claims usually focus on defined chemical structures (or formulations) and specific processes. In the CN system, it typically maps to one or more of the following: (1) product matter claims (the active ingredient and/or salts/polymorphs), (2) composition claims (formulations), (3) process claims (manufacture), and (4) use claims (methods of treatment or use in therapy).
A complete, clause-by-clause analysis of the exact claim scope (independent and dependent claims), the full claim set language, and a territory-by-territory landscape (family members, competing filings, granted status, and enforceable rights) requires the patent text and legal status documents for CN100577234 and its family.
No such patent-text or status content is provided in the request, and it is not possible to produce an accurate claim-by-claim scope mapping or a reliable landscape (priority, family members, cited documents, and infringement-relevant overlap) without those primary sources.
What is the claim scope of CN100577234 (product, formulation, process, and use)?
A proper scope assessment in China hinges on the precise wording of the claims, including:
- Independent claim(s): chemical structure definition or biological sequence definition (if applicable), the therapeutic indication, and any required parameters (dose ranges, administration routes, patient subpopulations).
- Dependent claim coverage: salts, solvates, polymorphs, stereochemistry, crystallinity, particle size, excipients, granulation steps, and manufacturing constraints.
- Process versus product coverage: whether the application is structured to block “making,” “using,” or “selling” through process claims, or whether it is framed as a pure composition claim.
- Markush-like ranges or optionality: whether claim terms are closed (specific exemplars only) or open (covering “selected from” lists or functional definitions).
- Therapeutic use wording: whether “treating” is anchored to a disease, a biomarker status, or a combination regimen.
A complete and accurate summary of these items for CN100577234 cannot be generated from the publication identifier alone.
How broad are the key claim elements in CN100577234?
To determine practical breadth for freedom-to-operate (FTO) and potential infringement, the analysis must quantify:
- How many structural variants are covered (e.g., salt/solvate coverage, polymorph coverage, stereoisomer coverage).
- Whether the claim uses numerical ranges (dose, concentration, pH, temperature, reaction conditions) or only fixed values.
- Whether the claim covers intermediate compounds or final compounds only.
- Whether the use claim covers a standalone monotherapy or also captures combination therapy (co-administration claims).
- Whether the specification supports additional claim-construction outcomes under CN practice (support for broad ranges, alternative embodiments, and claim term interpretations).
Without the actual claim language and specification excerpts, breadth can’t be grounded in the text.
What does the China patent landscape look like for CN100577234 (family, priority, grants, and blockers)?
A landscape analysis in China typically includes:
-
Family tree mapping
- Priority application(s) and dates
- Jurisdictions filed (CN, WO, US, EP, KR, JP)
- Whether CN claims were granted and which claims survived examination
-
Competing filings in China
- Other CN applications that cite similar structures or similar formulations
- Continuations/divisionals (where applicable)
- Follow-on patents for new salts, polymorphs, particle size, or methods of use
-
Regulatory patent linkage and enforcement relevance
- Whether the patent is listed for market entry protection (where applicable by CN NMPA linkage practice)
- Whether later BLA/ANDA/MAH approvals would trigger use-of-patent questions
-
Citation and obviousness risk
- Whether CN100577234’s novelty hinges on a specific example or a general genus
- Whether the closest prior art cited by the examiner is from earlier patent literature or earlier non-patent literature
These are determinable only by retrieving the official CN publication, the full claim set, and the examination/legal status records.
What is the actionable FTO-facing overlap structure around CN100577234?
For business decisions, landscape overlap must be expressed in a concrete risk matrix:
| Overlap type |
What it captures |
FTO impact if CN100577234 is strong |
| Product/substance overlap |
Same active ingredient or covered salt/polymorph |
Direct infringement risk for API or finished dosage |
| Formulation overlap |
Same excipient system or formulation parameters |
Risk shifts to dosage form manufacturing and sale |
| Method overlap |
Same patient population, dosing regimen, route |
Risk focuses on label claims and clinical use |
| Process overlap |
Same synthetic steps and conditions |
Risk shifts to API manufacturing route |
A true overlap map requires knowing exactly what CN100577234 claims and how broadly.
What to pull from CN100577234 for enforcement strategy (claim priorities, term limits, and claim drafting patterns)?
To support enforcement or design-around, a Bloomberg-style patent analysis usually extracts:
- Claim categories present in the filing (product, formulation, process, use).
- Scope drivers: which claim terms are broadest and which are most limiting.
- Structural anchors: core moiety and substituent sets, stereochemical requirements, and salt forms.
- Therapeutic anchors: named indications and whether combination regimens are claimed.
- Term and expiry math: filing/priority dates, likely patent term start in CN, and expected expiration window.
- Continuation risk: whether later family members (CN divisionals or later filings) extend coverage.
None of these can be computed or summarized without the text and legal timeline.
Key Takeaways
- CN100577234’s exact claim scope and its in-friction landscape position cannot be determined from the identifier alone.
- A claim-by-claim scope analysis in the China context must use the actual CN publication claim set and legal status records.
- A credible landscape requires family mapping, competitor filings in CN, and whether CN100577234 (or family members) is granted and enforceable.
FAQs
-
Does CN100577234 protect the active ingredient, the formulation, or both?
Depends on the actual independent and dependent claims in the CN publication.
-
Are method-of-treatment claims included in CN100577234?
Only the claim text can confirm presence, therapeutic anchors, and whether combination regimens are captured.
-
How is claim breadth typically constrained in CN drug patents like CN100577234?
By precise structure definitions, required salt/polymorph forms, dosing and route limitations, and numeric parameter ranges.
-
What does “landscape” mean in a China drug patent case?
Family members, related CN filings, granted/enforceable status, and overlap with regulatory and commercial embodiments.
-
How do competitors typically design around claims like those in CN drug filings?
By using non-covered salt/polymorph forms, alternative formulations, different dosing regimens/indications, or alternative synthetic routes if process claims are present.
References
[1] China National Intellectual Property Administration. CN100577234 (publication data and claim set).
[2] World Intellectual Property Organization. CN family/publication records related to CN100577234 (if applicable).
